Management of the aging risk factor for Parkinson's disease

Neurobiology of Aging

Volumn 35, Issue 4, 2014, Pages 847-857

  Phillipson, Oliver T ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Acetyl l carnitine; Aging; Alpha lipoic acid; Coenzyme Q10; Melatonin; Mitochondria; Nrf2; Parkinson's disease; PGC 1alpha

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALPHA SYNUCLEIN; CARBOHYDRATE; FATTY ACID; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; IRON; LEVACECARNINE; MELATONIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; THIOCTIC ACID; UBIDECARENONE; XENOBIOTIC AGENT;

AGING; ANTIOXIDANT ACTIVITY; BIOGENESIS; CELL LOSS; CONCENTRATION (PARAMETERS); ELECTRON TRANSPORT; ENERGY METABOLISM; ENZYME INHIBITION; ENZYME SYNTHESIS; GENE ACTIVITY; GENE EXPRESSION; GENE FUNCTION; HUMAN; INFLAMMATION; NEUROTRANSMISSION; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN MODIFICATION; REVIEW; RISK FACTOR;

ACETYL-L-CARNITINE; AGING; ALPHA LIPOIC ACID; COENZYME Q10; MELATONIN; MITOCHONDRIA; NRF2; PARKINSON'S DISEASE; PGC-1ALPHA;

ACETYLCARNITINE; ADENOSINE TRIPHOSPHATE; AGING; ALPHA-SYNUCLEIN; ANTIOXIDANT RESPONSE ELEMENTS; CARBOHYDRATE METABOLISM; ELECTRON TRANSPORT; ENERGY METABOLISM; FATTY ACIDS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; INFLAMMATION; MELATONIN; MITOCHONDRIA; NITRIC OXIDE; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEOSTASIS DEFICIENCIES; RISK FACTORS; THIOCTIC ACID; TRANSCRIPTION FACTORS; UBIQUINONE;

EID: 84891365207     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2013.10.073     Document Type: Review

References (176)

1. Aliev G., Liu J., Shenk J.C., Fishbach K., Pacheco G.J., Chen S.G., Obrenovich M.E., Ward W.F., Richardson A.G., Smith M.A., Gasimov E., Perry G., Ames B.S. Neuronal mitochondrial amelioration by feeding acetyl-L-carnitine and lipoic acid to aged rats. J.Cell Mol. Med. 2009, 13:320-333.
2. Allen S.J., Watson J.J., Shoemark D.K., Barua N.U., Patel N.K. GDNF, NGF and BDNF as therapeutic options for neurodegeneration. Pharmacol. Ther. 2013, 138:155-175.
3. Adi N., Mash D.C., Ali Y., Singer C., Shehadeh L., Papapetropoulos S. Melatonin MT1 and MT2 receptor expression in Parkinson's disease. Med. Sci. Monit. 2010, 16:BR61-BR67.
4. Anton-Tay F., Ramirez G., Martinez I., Benitez-King G. Invitro stimulation of protein kinase C by melatonin. Neurochem. Res. 1998, 23:601-606.
5. Antunes F., Han D., Rettori D., Cadenas E. Mitochondrial damage by nitric oxide is potentiated by dopamine in PC12 cells. Biochim. Biophys. Acta 2002, 1556:233-238.
6. Applegate M.A.B., Humphries K.M., Szweda L.I. Reversible inhibition of alpha-ketoglutarate dehydrogenase by hydrogen peroxide: glutathionylation and protection of lipoic acid. Biochemistry 2008, 47:473-478.
7. Arivazhagan P., Ramanathan K., Panneerselvam C. Effects of DL-alpha-lipoic acid on mitochondrial enzymes in aged rats. Chem. Biol. Interact. 2001, 138:189-198.
8. Armstrong K.J., Niles L.P. Induction of GDNF mRNA expression by melatonin in rat C6 glioma cells. Neuroreport 2002, 13:473-475.
9. Aureli T., Miccheli A., Ricciolini R., Di Cocco M.E., Ramacci M.T., Angelucci L., Ghardhi O., Conti F. Aging brain: effect of acetyl-L-carnitine treatment on rat brain energy and phospholipid metabolism. A study by 31P and 1H NMR spectroscopy. Brain Res. 1990, 526:108-112.
10. Aureli T., Di Cocco M.E., Pucetti C., Ricciolini R., Scalibastri M., Micceli A., Manetti C., Conti F. Acetyl-L-carnitine modulates glucose metabolism and stimulates glycogen synthesis in rat brain. Brain Res. 1998, 796:75-81.
11. Baecker P.A., Lee W.H., Verity A.N., Eglen R.M., Johnson R.M. Characterisation of a promoter for the human glial cell line-derived neurotrophic factor gene. Brain Res. Mol. Brain Res. 1999, 69:209-222.
12. Beach T.G., Adler C.H., Sue L., Vedders L., Lue L., White C.L., Akiyama H., Caviness J.N., Shill H.A., Sabbagh M.N., Walker D.G., Arizona Parkinson's Disease Consortium Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol. 2010, 119:689-702.
13. Beckman J.S. Peroxynitrite versus hydroxyl radical: the role of nitric oxide in superoxide-dependent cerebral injury. Ann. N. Y. Acad. Sci. 1994, 738:69-75.
14. Bender A., Krishnan K.J., Morris C.M., Taylor G.A., Reeve A.K., Perry R.H., Jaros E., Hersheson J.S., Betts J., Klopstock T., Taylor R.W., Turnbull D.M. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat. Genet. 2006, 38:515-517.
15. Beyer R.E., Degura-Aguilar J., Di Bernardo S., Cavazzoni M., Fato R., Fiorentini D., Galli M.C., Setti M., Landi L., Lenaz G. The role of DT-diaphorase in the maintenance of the reduced antioxidant form of coenzyme Q in membrane systems. Proc. Natl. Acad. Sci. U.S.A 1996, 93:2528-2532.
16. Bharat S., Cochran B.C., Hsu M., Liu J., Ames B.N., Anderson J.K. Pre-treatment with R-lipoic acid alleviates the effects of GSH depletion in PC12 cells: implications for Parkinson's disease therapy. Neurotoxicology 2002, 23:479-486.
17. Bodis-Wollner I., Chung E., Ghilardi M.F., Glover A., Onofrj M., Pasik P., Samson Y. Acetyl-levo-carnitine protects against MPTP-induced parkinsonism in primates. J. Neur. Transm. Park. Dis. Dement. Sec. 1991, 3:63-72.
18. Bolton R.F., Cornwall J., Phillipson O.T. Collateral axons of cholinergic pontine neurones projecting to midline, mediodorsal and parafascicular thalamic nuclei in the rat. J.Chem. Neuroanat 1993, 6:101-114.
19. Braak H., Del Tredici K., Rub U., de Vos R.A.I., Jansen Steur E.N.H., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 2003, 24:197-211.
20. Braidy N., Guillemin G.J., Mansour H., Chan-Ling T., Poljak A., Grant R. Age related changes in NAD+ metabolism oxidative stress and Sirt1 activity in wistar rats. PLoS One 2011, 6:e19194.
21. Brown G.C., Borutaite V. Inhibition of mitochondrial respiratory chain complex I by nitric oxide, peroxynitrite and S-nitrosothiols. Biochim. Biophys. Acta 2004, 1658:44-49.
22. Brydon L., Roka F., Petit L., de Coppet P., Tissot M., Barrett P., Morgan P.J., Nanoff C., Strosberg A.D., Jockers R. Dual signaling of human Mel1a melatonin receptors via G(i2), G(i3) and G(q11) proteins. Mol. Endocrinol. 1999, 13:2025-2038.
23. Burke W.J., Kumar V.B., Pandey N., Panneton W.M., Gan Q., Franko M.W., O'Dell M., Li S.W., Pan Y., Chung H.D., Galvin J.E. Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine. Acta Neuropathol. 2008, 115:193-203.
24. Calabrese V., Ravagna A., Colombrita C., Scapagnini G., Guagliano E., Calvani M., Butterfield D.A., Guiffrida Stella A.M. Acetylcarnitine induces heme oxygenase in rat astrocytes and protects against oxidative stress: involvement of the transcription factor Nrf2. J. Neurosci. Res. 2005, 79:509-552.
25. Cali T., Ottolini D., Negro A., Brini M. Alpha-synuclein controls mitochondrial calcium homeostasis by enhancing endoplasmic reticulum-mitochondria interactions. J. Biol. Chem. 2012, 287:17914-17929.
26. Calkins M.J., Johnson D.A., Townsend J.A., Vargas M.R., Dowell J.A., Williamson T.P., Kraft A.D., Lee J.M., Li J., Johnson J.A. The Nrf/ARE pathway as a potential therapeutic target in neurodegenerative disease. Antioxid. Redox Signal. 2009, 11:497-508.
27. Carretero M., Escames G., Lopez L.C., Venegas C., Dayoub J.C., Garcia L., Acuna-Castroviejo D. Long-term melatonin administration protects brain mitochondria from aging. J.Pineal Res. 2009, 47:192-200.
28. Cassarino D.S., Bennett J.P. An evaluation of the role of mitochondria in neurodegenerative diseases. Brain Res. Rev. 1999, 29:1-25.
29. Chinta S.J., Mallajosyula J.K., Rane A., Andersen J.K. Mitochondrial alpha-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy invivo. Neurosci. Lett. 2010, 486:235-239.
30. Choi H., Park H.H., Koh S.H., Choi N.Y., Yu H.J., Park J., Lee Y.J., Lee K.Y. Coenzyme Q10 protects against amyloid beta-induced neuronal cell death by inhibiting oxidative stress and activating the PI3K pathway. Neurotoxicology 2012, 33:85-90.
31. Chu Y., Kordower J.H. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: is this the target for Parkinson's disease?. Neurobiol. Dis. 2007, 25:134-149.
32. Cleeter M.W.J., Cooper J.M., Schapira A.H.V. Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: evidence for free radical involvement. J.Neurochem. 1992, 58:786-789.
33. Clementi E., Brown G.C., Feelisch M., Moncada S. Persistent inhibition of cell respiration by nitric oxide: crucial role of S-nitrosylation of mitochondrial complex I and protective action of glutathione. Proc. Natl. Acad. Sci. U.S.A 1998, 95:7631-7636.
34. Clinical Trials.gov 2011. NCT00740714 effects of coenzyme Q10 (CoQ) in Parkinson disease (QE3).
35. Cremer D.R., Rabeler R., Roberts A., Lynch B. Long term safety of alpha-lipoic acid (ALA) consumption: a 2-year study. Regul. Toxicol. Pharmacol. 2006, 46:193-201.
36. Cohen G. Enzymatic/nonenzymatic sources of oxyradicals and regulation of antioxidant defenses. Ann. N. Y. Acad. Sci. 1994, 738:8-14.
37. Collier T.J., Kanaan N.M., Kordower J.H. Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates. Nat. Rev. Neurosci. 2011, 12:359-366.
38. Dalfo E., Portero-Otin M., Ayala V., Martinez A., Pamplona R., Ferrer I. Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J.Neuropath. Exp. Neurol. 2005, 64:816-830.
39. Darbin O. The aging striatal dopamine function. Parkinsonism Relat. Disord. 2012, 18:426-432.
40. De Grandis D., Minardi C. Acetyl-L-carnitine in the treatment of diabetic neuropathy. A long-term, randomised double-blind, placebo-controlled study. Drugs. RD 2002, 3:223-231.
41. Dexter D.T., Holley A.E., Flitter W.D., Slater T.F., Wells F.R., Daniel S.E., Lees A.J., Jenner P., Marsden C.D. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov. Disord. 1994, 9:92-97.
42. Devi L., Raghavendran V., Prabhu B.M., Avadhani N.G., Anandatheerthavarada H.K. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J.Biol. Chem. 2008, 283:9089-9100.
43. Dinkova-Kostova A.T., Talalay P. NAD(P)H:quinone acceptor oxoreductase (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector. Arch. Biochem. Biophys. 2010, 501:116-123.
44. Drolet R.E., Cannon J.R., Montero L., Greenamyre J.T. Chronic rotenone exposure reproduces Parkinson's disease gastrointestinal neuropathology. Neurobiol. Dis. 2009, 36:96-102.
45. Dunning C.J., George S., Brundin P. What's to like about the prion-like hypothesis for the spreading of aggregated alpha-synuclein in Parkinson disease?. Prion 2013, 7:92-97.
46. Editorial What constitutes a physiological concentration of melatonin?. J.Pineal Res. 2003, 34:79-80.
47. Ernster L., Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim. Biophys. Acta 1995, 1271:195-204.
48. Escames G., Lopez A., Garcia J.A., Garcia L., Acuna-Castroviejo D., Garcia J.J., Lopez L.C. The role of mitochondria in brain aging and the effects of melatonin. Curr. Neuropharmacol. 2010, 8:182-193.
49. Flier J., Van Muiswinkel F.L., Jongenelen C.A., Drukarch B. The neuroprotective antioxidant alpha-lipoic acid induces detoxication enzymes in cultured astroglial cells. Free Radic. Res. 2002, 36:695-699.
50. Fontaine E., Eriksson O., Ichas F., Bernardi P. Regulation of the permeability transmission pore in skeletal muscle mitochondria. J.Biol. Chem. 1998, 273:12662-12668.
51. Galano A. On the direct scavenging activity of melatonin towards hydroxyl and a series of peroxyl radicals. Phys. Chem. Chem. Phys. 2011, 13:7178-7188.
52. Giasson B.I., Duda J.E., Murray I.V., Chen Q., Souza J.M., Hurtig H.I., Ischiropoulos H., Trojanowski J.Q., Lee V.M. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 2000, 290:985-989.
53. Gibson G.E., Kingsbury A.E., Xu H., Lindsay J.G., Daniel S., Foster O.J., Lees A.J., Blass J.P. Deficits in a tricarboxylic acid cycle enzyme in brains from patients with Parkinson's disease. Neurochem. Int. 2003, 43:129-135.
54. Gille G., Hung S.T., Reichmann H., Rausch W.D. Oxidative stress to dopaminergic neurons as models of Parkinson's disease. Ann. N. Y. Acad. Sci. 2004, 1018:533-540.
55. Giudice A., Arra C., Turco M.C. Review of molecular mechanisms involved in the activation of the Nrf2-ARE signaling pathway by chemopreventive agents. Methods. Mol. Biol. 2010, 647:37-74.
56. Gorini A., D'Angelo A., Villa R.F. Action of L-acetylcarnitine on different cerebral mitochondrial populations from cerebral cortex. Neurochem. Res. 1998, 23:1485-1491.
57. Hagen T.M., Ingersoll R.T., Wehr C.M., Lykkesfeldt J., Vinarsky V., Bartholomew J.C., Song M.-H., Ames B.N. Acetyl-L-carnitine fed to old rats partially restores mitochondrial function and ambulatory activity. Proc. Natl. Acad. Sci. U.S.A 1998, 95:9562-9566.
58. Hagen T.M., Liu J., Lykkesfeldt J., Wehr C.M., Ingersoll R.T., Vinarsky V., Bartholomew J.C., Ames B.N. Feeding acetyl-L-carnitine and lipoic acid to old rats significantly improves metabolic function while decreasing oxidative stress. Proc. Natl. Acad. Sci. U.S.A 2002, 99:1870-1875.
59. Halliday G.M. Thalamic changes in Parkinson's disease. Parkinsonism Relat. Disord. 2009, 15(Suppl.3):S152-S155.
60. Halliwell B. Reactive oxygen species and the central nervous system. J.Neurochem. 1992, 59:1609-1623.
61. Han D., Handelman G., Marcocci L., Sen C.K., Roy S., Kobuchi H., Tritschler H.J., Flohe L., Packer L. Lipoic acid increases de novo synthesis of cellular glutathione by improving cystine utilisation. Biofactors 1997, 6:321.
62. Hargreaves I.P., Lane A., Sleiman P.M.A. The coenzyme Q10 status of the brain regions of Parkinson's disease patients. Neurosci. Lett. 2008, 447:17-19.
63. Harman D. Aging: a theory based on free radical and radiation chemistry. J. Gerontol. 1956, 11:298-300.
64. Harris J.P., Calvert J.E., Phillipson O.T. Processing of spatial contrast in peripheral vision in Parkinson's disease. Brain 1992, 115:1447-1457.
65. Hauser D.N., Hastings T.G. Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism. Neurobiol. Dis. 2013, 51:35-42.
66. Henchcliffe C., Beal M.F. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat. Clin. Pract. Neurol. 2008, 4:600-609.
67. Hindle J.V. Ageing, neurodegeneration and Parkinson's disease. Age Ageing 2010, 39:156-161.
68. Humphries K.M., Szweda L.I. Selective inactivation of alpha ketoglutarate dehydrogenase and pyruvate dehydrogenase; reaction of lipoic acid with 4-hydroxy-2-nonenal. Biochemistry 1998, 37:15835-15841.
69. Hung S.Y., Liou H.C., Kang K.H., Wu R.M., Wen C.C., Fu W.M. Overexpression of heme oxygenase-1 protects dopaminergic neurons against 1-methyl-4-phenylpyridium-induced neurotoxicity. Mol. Pharmacol 2008, 74:1564-1575.
70. Hung S.Y., Liou H.C., Fu W.M. The mechanism of heme oxygenase-1 action involved in the enhancement of neurotrophic factor expression. Neuropharmacology 2010, 58:321-329.
71. Hunt A.E., Al-Ghoul W.M., Gillette M.U., Dubocovich M.L. Activation of MT2 melatonin receptors in rat suprachiasmatic nucleus phase advances the circadian clock. Am. J. Physiol: Cell Physiol. 2001, 280:C110-C118.
72. Imperato A., Ramacci M.T., Angelucci L. Acetyl-L-carnitine enhances acetylcholine release in the striatum and hippocampus of awake freely moving rats. Neurosci. Lett. 1989, 107:251-255.
73. Jain S., Siegle G.J., Gu C., Moore C.G., Ivanco L.S., Jennings J.R., Steinhauer S.R., Studenski S., Greenamyre J.T. Autonomic insufficiency in pupillary and cardiovascular systems in Parkinson's disease. Parkinsonism Relat. Disord. 2011, 17:119-122.
74. Jakel R.J., Townsend J.A., Kraft A.D., Johnson J.A. Nrf2-mediated protection against 6-hydroxydopamine. Brain Res. 2007, 1144:192-201.
75. Jazwa A., Rojo A.I., Innamorato N.G., Hesse M., Fernandez-Riuz J., Cuadrado A. Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism. Antioxid. Redox Signal. 2011, 14:2347-2360.
76. Jellinger K.A. Post mortem studies in Parkinson's disease - is it possible to detect brain areas for specific symptoms?. J.Neural Transm. Suppl. 1999, 56:1-29.
77. Jia Z., Hallur S., Zhu H., Li Y., Misra H.P. Potent upregulation of glutathione and NAD(P)H:quinone oxoreductase 1 by alpha-lipoic acid in human neuroblastoma SH-SY5Y cells: protection against neurotoxicant-elicited cytotoxicity. Neurochem. Res. 2008, 33:790-800.
78. Jiang T., Yin F., Yao J., Brinton R.D., Cadenas E. Lipoic acid restores age-associated impairment of brain energy metabolism through the modulation of Akt/JNK signaling and PGC1alpha transcriptional pathway. Aging Cell 2013, 10.1111/acel.12127.
79. Jones L.L., McDonald D.A., Borum P.R. Acylcarnitines: role in brain. Prog. Lipid Res. 2010, 49:61-75.
80. Kaidery N.A., Banerjee R., Yang L., Smirnova N.A., Hushpulian D.M., Liby K.T., Williams C.R., Yamamoto M., Kensler T.W., Ratan R.R., Sporn M.B., Beal M.F., Gazaryan I.G., Thomas B. Targeting Nrf2-mediated gene transcription by extremely potent synthetic triterpenoids attenuate dopaminergic neurotoxicity in the MPTP mouse model of Parkinson's disease. Antioxid. Redox Signal. 2013, 18:139-157.
81. Kirik D., Georgievska B., Bjorklund A. Localised striatal delivery of GDNF as a treatment for Parkinson's disease. Nat. Neurosci. 2004, 7:105-110.
82. Kish S.J., Shannak K., Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N.Engl. J. Med. 1988, 318:876-880.
83. Kish S.J., Shannak K., Rajput A., Deck J.H., Hornykiewicz O. Aging produces a specific pattern of striatal dopamine loss: implications for the etiology of idiopathic Parkinson's disease. J.Neurochem. 1992, 58:642-648.
84. Kong P.J., Byun J.S., Lim S.Y., Lee J.J., Hong S.J., Kwon K.J., Kim S.S. Melatonin induces Akt phosphorylation through melatonin receptor-and PI3K-dependent pathways in primary astrocytes. Korean J. Physiol. Pharmacol. 2008, 12:37-41.
85. Kooncumchoo P., Sharma S., Porter J., Govitrapong P., Ebadi M. Coenzyme Q(10) provides neuroprotection in iron-induced apoptosis in dopaminergic neurons. J.Mol. Neurosci. 2006, 28:125-141.
86. Korotchkina L.G., Yang H., Tirosh O., Packer L., Patel M.S. Protection by thiols of the mitochondrial complexes from 4-hydroxy-2-nonenal. Free Radic. Biol. Med. 2001, 30:992-999.
87. Kotler M., Rodriguez C., Sainz R.M., Antolin I., Menendez-Pelaez A. Melatonin increases gene expression for antioxidant enzymes in rat brain cortex. J.Pineal Res. 1998, 24:83-89.
88. Kristal B.S., Conway A.D., Brown A.M., Jian J.C., Ulluci P.A., Li S.W., Burke W.J. Selective dopaminergic vulnerability: 3,4-dihydroxyphenylacetaldehyde targets mitochondria. Free Radic. Biol. Med. 2001, 30:924-931.
89. Kumar M.J., Nicholls D.G., Andersen J.K. Oxidative alpha-ketoglutarate dehydrogenase inhibition via subtle elevations in monoamine oxidase B levels results in loss of spare respiratory capacity: implications for Parkinson's disease. J.Biol. Chem. 2003, 278:46432-46439.
90. Kwak M.-K., Wakabayashi N., Itoh K., Motobashi H., Yamamoto M., Kensler T.W. Modulation of gene expression by cancer chemopreventative dithiolethiones through the Keap-Nrf2 pathway. Identification of novel gene clusters for cell survival. J.Biol. Chem. 2003, 278:8135-8145.
91. Lamensdorf I., Eisenhofer G., Harvey-White J., Nechustan A., Kirk K., Kopin I.J. 3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells. Brain Res. 2000, 868:191-201.
92. Lastres-Becker I., Ulusoy A., Innamorato N.G., Sahin G., Rabano A., Kirik D., Cuadrado A. Alpha-synuclein expression and Nrf2 deficiency cooperate to aggravate protein aggregation, neuronal death and inflammation in early-stage Parkinson's disease. Hum. Mol. Genet. 2012, 21:3173-3192.
93. Lemoine P., Garfinkel D., Laudon M., Zisapel N. Prolonged-release melatonin for insomnia- an open label long term study of efficacy, safety and withdrawal. Ther.Clin. Risk Manag. 2011, 7:301-311.
94. Leon J., Vives F., Crespo E., Camacho E., Espinosa A., Gallo M.A., Escames G., Acuna-Castroviejo D. Modification of nitric oxide synthase activity and neuronal response in rat striatum by melatonin and kynurenine derivatives. J.Neuroendocrinol. 1998, 10:297-302.
95. Leon J., Macias M., Escames G., Camacho E., Khaldi H., Martin M., Espinosa A., Gallo M.A., Acuna-Castroviejo D. Structure related inhibition of calmodulin-dependent neuronal nitric-oxide synthase activity by melatonin and synthetic kynurenines. Mol. Pharmacol. 2000, 58:967-975.
96. Leon J., Escames G., Rodriguez M.I., Lopez L.C., Tapias V., Entrena A., Camacho E., Carrion M.D., Gallo M.A., Espinosa A., Tan D.X., Reiter R.J., Acuna-Castroviejo D. Inhibition of neuronal nitric oxide synthase activity by N1-acetyl-5-methoxykynuramine, a brain metabolite of melatonin. J. Neurochem. 2006, 98:2023-2033.
97. Lin L.-F.H., Doherty D.H., Lile J.D., Bektesh S., Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993, 260:1130-1132.
98. Liu J. The effects and mechanisms of mitochondrial nutrient alpha-lipoic acid on improving age-associated mitochondrial and cognitive dysfunction: an overview. Neurochem. Res. 2008, 33:194-203.
99. Long J., Gao F., Tong L., Cotman C.W., Ames B.N., Liu J. Mitochondrial decay in the brains of old rats: ameliorating effect of alpha-lipoic acid and acetyl-L-carnitine. Neurochem. Res. 2009, 34:755-763.
100. Long J., Liu C., Sun L., Gao H., Liu J. Neuronal mitochondrial toxicity of malondialdehyde: inhibitory effects on respiratory function and enzyme activities in rat brain mitochondria. Neurochem. Res. 2009, 34:786-794.
101. Lopez A., Garcia J.A., Escames G., Venegas C., Ortiz F., Lopez L.C., Acuna-Castroviejo D. Melatonin protects the mitochondria from oxidative damage reducing oxygen consumption, membrane potential, and superoxide anion production. J. Pineal Res. 2009, 46:188-198.
102. Mann V.M., Cooper J.M., Krige D., Daniel E., Schapira A.H.V., Marsden C.D. Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. Brain 1992, 115:333-342.
103. Marchitti S.A., Dietrich R.A., Vasiliou V. Neurotoxicity and metabolism of the catecholamine-derived 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde: the role of aldehyde dehydrogenase. Pharmacol. Rev. 2007, 59:125-150.
104. Martin L.J. Mitochondrial pathobiology in Parkinson's disease and amyotrophic lateral sclerosis. J. Alzheimers Dis. 2010, 20(Suppl. 2):S335-S356.
105. Martin M., Macias M., Escames G., Leon J., Acuna-Castroviejo D. Melatonin but not vitamins C and E maintains glutathione homeostasis in t-butyl hydroperoxide induced mitochondrial oxidative stress. FASEB J. 2000, 14:1677-1697.
106. Martin M., Macias M., Leon J., Escames G., Khaldy H., Acuna-Castroviejo D. Melatonin increases the activity of the oxidative phosphorylation enzymes and the production of ATP in rat brain and liver mitochondria. Int. J. Biochem. Cell Biol. 2002, 34:348-357.
107. Martin V., Sainz R.M., Antolin I., Mayo J.C., Herrera F., Rodriguez C. Several antioxidant pathways are involved in astrocyte protection by melatonin. J.Pineal Res. 2002, 33:204-212.
108. Masana M.I., Dubocovich M.L. Melatonin receptor signaling: finding the path through the dark. Sci STKE. 2001, (Issue 107):pe39.
109. Matthews R.T., Yang L., Browne S., Baik M., Beal M.F. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc. Natl. Acad. Sci. U.S.A 1998, 95:8892-8897.
110. Mayo J.C., Sainz R.M., Antoli I., Herrera F., Martin V., Rodriguez C. Melatonin regulation of antioxidant enzyme gene expression. Cell Mol. Life Sci. 2002, 59:1706-1713.
111. McCarthy S., Somayajulu M., Sikorska M., Borowy- Borowski H., Pandey S. Paraquat induces oxidative stress and neuronal cell death; neuroprotection by water-soluble Coenzyme Q10. Toxicol. Appl. Pharmacol. 2004, 201:21-31.
112. McKenna M.C., Waagepetersen H.S., Schousboe A., Sonnewald U. Neuronal and astrocytic shuttle mechanisms for cytosolic-mitochondrial transfer of reducing equivalents: current evidence and pharmacological tools. Biochem. Pharmacol. 2006, 71:399-407.
113. McMillan C.R., Sharma R., Ottenhof T., Niles L.P. Modulation of tyrosine hydroxylase expression by melatonin in human SH-SY5Y neuroblastoma cells. Neurosci. Lett. 2007, 419:202-206.
114. Mischley L.K., Allen J., Bradley R. Coenzyme Q10 deficiency in patients with Parkinson's disease. J.Neurol. Sci. 2012, 318:72-75.
115. Mizuno Y., Matuda S., Yoshino H., Mori H., Hattori N., Ikebe S. An immunohistochemical study on alpha-ketoglutarate dehydrogenase complex in Parkinson's disease. Ann. Neurol. 1994, 35:204-210.
116. Moncada S., Bolanos J.P. Nitric oxide, cell bioenergetics and neurodegeneration. J.Neurochem. 2006, 97:1676-1689.
117. Moon Y., Lee K.H., Park J.H., Geum D., Kim K. Mitochondrial membrane depolarisation and the selective death of dopaminergic neurons by rotenone: protective effect of coenzyme Q10. J.Neurochem. 2005, 93:1199-1208.
118. Moretto G., Walker D.G., Lanteri P., Taioli F., Zaffagnini S., Xu R.Y., Rizzuto N. Expression and regulation of glial-cell-line-derived neurotrophic factor (GDNF) mRNA in human astrocytes invitro. Cell Tissue Res. 1996, 286:257-262.
119. Mudo G., Makela J., Liberto V.D., Tselykh T.V., Olivieri M., Piepponen P., Eriksson O., Malkia A., Bonomo A., Kairisalo M., Aquirre J.A., Korhonen L., Belluardo N., Lindholm D. Transgenic expression and activation of PGC-1alpha protect dopaminergic neurons in the MPTP mouse model of Parkinson's disease. Cell. Mol. Life Sci. 2012, 69:1153-1165.
120. Mytilineou C., Werner P., Molinari S., DiRocco A., Cohen G., Yahr M.D. Impaired oxidative decarboxylation of pyruvate in fibroblasts from patients with Parkinson's disease. J.Neural Transm. Park. Dis. Dement. Sect. 1994, 8:223-228.
121. Nicholls D.G., Budd S.L. Mitochondria and neuronal survival. Physiol. Rev 2000, 80:315-360.
122. Niles L.P., Armstrong K.J., Rincon Castro L.M., Dao C.V., Sharma R., McMillan C.R., Doering L.C., Kirkham D.L. Neural stem cells express melatonin receptors and neurotrophic factors: colocalisation of the MT1 receptor with neuronal and glial markers. BMC Neurosci. 2004, 5:41.
123. Okatani Y., Wakatsuki A., Reiter R.J. Melatonin protects hepatic mitochondrial respiratory chain activity in senescence-accelerated mice. J.Pineal Res. 2002, 32:143-148.
124. Olanow C.W. Ascientific rationale for protective therapy in Parkinson's disease. J.Neural Transm. Gen. Sect. 1993, 91:161-180.
125. Ono K., Mochizuki H., Ikeda T., Nihira T., Takasaki J.I., Teplow D.B., Yamada M. Effect of melatonin on alpha-synuclein self-assembly and cytotoxicity. Neurobiol. Aging 2012, 33:2172-2185.
126. Packer L. Antioxidant properties of lipoic acid and its therapeutic effects in prevention of diabetes complications and cataracts. Ann. N. Y. Acad. Sci 1994, 738:257-264.
127. Packer L., Cadenas E. Lipoic acid: energy metabolism and redox regulation of transcription and cell signaling. J.Clin. Biochem. Nutr. 2011, 48:26-32.
128. Pahahill P.A., Lozano A.M. The pedunculopontine nucleus and Parkinson's disease. Brain 2000, 123:1767-1783.
129. Paradies G., Petrosillo G., Paradies V., Reiter R.J., Ruggiero F.M. Melatonin, cardiolipin and mitochondrial bioenergetics in health and disease. J. Pineal Res. 2010, 48:297-310.
130. Parker W.D., Parks J.K., Swerdlow R.H. Complex I deficiency in Parkinson's disease frontal cortex. Brain Res. 2008, 1189:215-218.
131. Petersen D.R., Doorn J.A. Reactions of 4-hydroxynonenal with proteins and cellular targets. Free Radic. Biol. Med. 2004, 37:937-945.
132. Phillipson O.T. Inhibition of aging in Parkinson's disease: a case study. J.Altern. Complement Med. 2013, 19:851.
133. Radunovic A., Porto W.G., Zeman S., Leigh P.N. Increased mitochondrial superoxide dismutase activity in Parkinson's disease but not amyotrophic lateral sclerosis motor cortex. Neurosci. Lett. 1997, 239:105-108.
134. Ramsey C.P., Glass C.A., Montgomery M.B., Lindl K.A., Ritson G.P., Chia L.A., Hamilton R.L., Chu C.T., Jordan-Sciutto K.L. Expression of Nrf2 in neurodegenerative diseases. J.Neuropathol. Exp. Neurol. 2007, 66:75-85.
135. Reiter R.J., Guerrero J.M., Garcia J.J., Acuna-Castroviejo D. Reactive oxygen intermediates, molecular damage and aging. Relation to melatonin. Ann. N. Y. Acad. Sci. 1998, 854:410-424.
136. Saavedra A., Baltazar G., Duarte E.P. Driving GDNF expression: the green and the red traffic lights. Progr. Neurobiol. 2008, 86:186-215.
137. Schapira A.H.V., Cooper J.M., Dexter D., Clark J.B., Jenner P., Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. J.Neurochem. 1990, 54:823-827.
138. Schmelzer C., Linder I., Rimbach G., Nicklovitz P., Menke T., Doring F. Functions of coenzyme Q10 in inflammation and gene expression. Biofactors 2008, 32:179-183.
139. Schults C.W., Haas R.H., Passov D., Beal M.F. Coenzyme Q10 levels correlate with the activities of complex I and II/III in mitochondria from parkinsonian and non-parkinsonian subjects. Ann. Neurol. 1997, 42:261-264.
140. Schulz J.B., Matthews R.T., Muqit M.M.K., Browne S.E., Flint Beal M. Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. J.Neurochem. 1995, 64:936-939.
141. Seabra M.L., Bignotto M., Pinto R.L., Tufik S. Randomized, double-blind clinical trial, controlled with placebo, of the toxicology of chronic melatonin treatment. J.Pineal Res. 2000, 29:193-200.
142. Sershen H., Harsing L.G., Banay-Schwartz M., Hashim A., Ramacci M.T., Lajtha A. Effect of acetyl-L-carnitine on the dopaminergic system in aging brain. J.Neurosci. Res. 1991, 30:555-559.
143. Sharma R., McMillan C.R., Tenn C.C., Niles L.P. Physiological neuroprotection by melatonin in a 6-hydroxydopamine model of Parkinson's disease. Brain Res. 2006, 1068:230-236.
144. Shay K.P., Moreau R.F., Smith E.J., Smith A.R., Hagen T.M. Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochim. Biophys. Acta 2009, 1790:1149-1160.
145. Shigenaga M.K., Hagen T.M., Ames B.N. Oxidative damage and mitochondrial decay in aging. Proc. Natl. Acad. Sci. U.S.A 1994, 91:10771-10778.
146. Sian J., Dexter D.T., Lees A.J., Daniel S., Agid Y., JavoyAgid F., Jenner P., Marsden C.D. Alterations in glutathione levels in Parkinson's disease patients and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol. 1994, 36:348-355.
147. Smeland O.B., Meisingset T.W., Borges K., Sonnewald U. Chronic acetyl-L-carnitine alters brain energy metabolism and increases noradrenaline and serotonin content in healthy mice. Neurochem. Int. 2012, 61:100-107.
148. Sohmiya M., Tanaka M., Tak N.W., Yanagisawa M., Tanino Y., Suzuki Y., Okamoto K., Yamamoto Y. Redox status of plasma coenzyme Q10 indicates elevated systemic oxidative stress in Parkinson's disease. J.Neurol. Sci. 2004, 223:161-166.
149. Somayajulu M., McCarthy S., Hung M., Sikorska M., Borowy-Borowski H., Pandey S. Role of mitochondria in neuronal cell death induced by oxidative stress; neuroprotection by Coenzyme Q10. Neurobiol. Dis. 2005, 18:618-627.
150. Spindler M., Beal M.F., Henchcliffe C. Coenzyme Q effects in neurodegenerative disease. Neuropsych. Dis. Treat. 2009, 5:597-610.
151. St-Pierre J., Drori S., Uldry M., Silvaggi J.M., Rhee J., Jager S., Handschin C., Zheng K., Lin J., Yang W., Simon D.K., Bachoo R., Spiegelman B.M. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 2006, 127:397-408.
152. Suh J.H., Shenvi S.V., Dixon B.M., Liu H., Jaiswal A.K., Liu R.-M., Hagen T.M. Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid. Proc. Natl. Sci. U.S.A 2004, 101:3381-3386.
153. Suh J.H., Moreau R., Heath S.H., Hagen T.M. Dietary supplementation with (R)-alpha-lipoic acid reverses the age-related accumulation of iron and depletion of antioxidants in the rat cerebral cortex. Redox Rep. 2005, 10:52-60.
154. Surh Y.J., Kundu J.K., Li M.H., Na H.K., Cha Y.N. Role of Nrf2-mediated heme oxygenase-1 upregulation in adaptive survival response to nitrosative stress. Arch. Pharm. Res. 2009, 32:1163-1176.
155. Suter-Crazzolara C., Unsicker K. GDNF mRNA levels are induced by FGF-2 in rat C6 glioblastoma cells. Brain Res. Mol. Brain Res. 1996, 41:175-182.
156. Swerdlow R.H. Mitochondrial Medicine and the Neurodegenerative Mitochondriopathies. Pharmaceuticals (Basel) 2009, 2:150-167.
157. Tan D.X., Manchester L.C., Sainz R.M., Mayo J.C., Leon J., Hardeland R., Poeggeler B., Reiter R.J. Interactions between melatonin and nicotinamide nucleotide: NADH preservation in cells and cell-free systems by melatonin. J. Pineal Res. 2005, 39:185-194.
158. Tan D.X., Manchester L.C., Terron M.P., Flores L.J., Reiter R.J. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species?. J.Pineal Res. 2007, 42:28-42.
159. Tapias V., Escames G., Lopez L.C., Lopez A., Camacho E., Carrion M.D., Entrena A., Gallo M.A., Espinosa A., Acuna-Castroviejo D. Melatonin and it's brain metabolite N(1)-acetyl-5-methoxykynuramine prevent mitochondrial nitric oxide synthase induction in parkinsonian mice. J.Neurosci. Res. 2009, 87:3002-3010.
160. Tempesta E., Janiri L., Pirrongelli C. Stereospecific effects of acetylcarnitine on the spontaneous activity of brainstem neurones and their responses to acetylcholine and serotonin. Neuropharmacology 1985, 24:43-50.
161. Triana G., Vallegi S., Bernardi R., Rizzo M., Calvani M., Nicolai R., Mosconi L., Durante M., Brunelli M. Identification of differentially expressed genes induced in the rat brain by acetyl-L-carnitine as evidenced by suppression subtractive hybridisation. Brain Res. Mol. Brain Res. 2004, 132:57-63.
162. Tufekci K.U., Civi Bayin E., Genc S., Genc K. The Nrf2/ARE pathway: a Promising Target to Counteract Mitochondrial Dysfunction in Parkinson's Disease. Parkinsons Dis. 2011, 2011:314082. 10.4061/2011/314082.
163. Uz T., Arslan A.D., Kurtimcu M., Imbesi M., Arkhisaroglu Y., Dwivedi Y., Pandey G.N., Manev H. The regional and cellular expression profile of the melatonin receptor MT1 in the central dopaminergic system. Brain Res. Mol. Brain Res. 2005, 136:45-53.
164. Verity A.N., Wyatt T.L., Hajos B., Eglen R.M., Baecker P.A., Johnson R.M. Regulation of glial cell line-derived neurotrophic factor release from rat C6 glioblastoma cells. J.Neurochem. 1998, 70:531-539.
165. Virmani M.A., Biseli R., Spadoni A., Rossi S., Corsico N., Calvani M., Fattorossi A., DeSimone C., Arrigoni-Martelli E. Protective actions of L-carnitine and acetyl-L-carnitine on the neurotoxicity evoked by mitochondrial uncoupling or inhibitors. Pharmacol. Res. 1995, 32:383-389.
166. Wareski P., Vaarmann A., Choubey V., Safiulina D., Liiv J., Kuum M., Kaasik A. PGC-1{alpha} and PGC-1{beta} regulate mitochondrial density in neurons. J.Biol. Chem. 2009, 284:21379-21385.
167. Witt-Enderby P.A., McKenzie R.S., McKeon R.M., Carroll E.A., Bordt S.L., Melan M.A. Melatonin induction of filamentous structures in non-neuronal cells that is dependent on expression of the human mt1 melatonin receptor. Cell. Motil. Cytoskel. 2000, 46:28-42.
168. Woodbury D., Schaar D.G., Ramakrishnan L., Black I.B. Novel structure of the human GDNF gene. Brain Res. 1998, 803:95-104.
169. Xia L., Nordman T., Olsson J.M., Damdimopoulos A., Bjorkhem-Bergman L., Nalvarte I., Eriksson L.C., Arner E.S.J., Spyrou G., Bjornstedt M. The mammalian cytosolic selenoenzyme thioredoxin reductase reduces ubiquinone. A novel mechanism for defense against oxidative stress. J.Biol. Chem. 2003, 278:2141-2146.
170. Yamamoto T., Maruyama W., Kato Y., Yi H., Shamoto-Nagai M., Tanaka M., Sato Y., Naoi M. Selective nitration of mitochondrial complex I by peroxynitrite: involvement in mitochondria dysfunction and cell death of dopaminergic SH-SY5Y cells. J.Neural Transm. 2002, 109:1-13.
171. Yoritaka A., Hattori N., Uchida K., Tanaka M., Stadtman E.R., Mizuno Y. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A 1996, 93:2696-2701.
172. Youdim M.B.H., Lavie L. Selective MAO-A and B inhibitors, radical scavengers and nitric oxide synthase inhibitors in Parkinson's disease. Life Sci. 1994, 55:25-26.
173. Zhang H., Jia H., Liu J., Ao N., Yan B., Shen W., Wang X., Li X., Luo C., Liu L. Combined R-alpha-lipoic acid and acetyl-L-carnitine exerts efficient preventative effects in a cellular model of Parkinson's disease. J. Cell. Mol. Med. 2010, 14:215-225.
174. Zheng B., et al. PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease. Sci. Transl. Med. 2010, 2:52ra73.
175. Zimmer G., Mainka L., Kruger E. Dihydrolipoic acid activates oligomycin-sensitive thiol groups and increases ATP synthesis in mitochondria. Arch.Biochem. Biophys. 1991, 288:609-613.
176. Zubay G.L. Biochemistry 1998, Wm.C. Brown Publishers. fourth ed.